CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Vertex Pharmaceuticals Incorporated

VRTX
$130.14BLarge Cap

Next catalyst

PDUFANov 30, 2026in 34 days

Povetacicept

IgA nephropathy

FDA decision pageSource

Get an email about VRTX's next catalysts

Track Vertex Pharmaceuticals (VRTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 15 more upcoming events in our data (Phase 3 readout, earnings, Phase 2 readout).See the timeline

Catalyst Timeline

16 upcoming, 0 past

Phase 3

VX-121/TEZ/D-IVA Phase 3 Est. Readout

October 2026~VX-121/TEZ/D-IVA822

Primary completion for VX-121/TEZ/D-IVA trial (NCT05444257) in Cystic Fibrosis

Source
Earnings

VRTX Earnings Report

Nov 2, 2026

EPS Est: $4.36 | FQ end Sep/2026 | Call: amc

PDUFANext

FDA PDUFA Date povetacicept

Nov 30, 2026Povetacicept

For IgA nephropathy. BLA, accelerated approval, Priority Review. Verified against the company announcement on 2026-10-16.

Source
Phase 2

IVA Phase 2 Est. Readout

Q4 2026~QIVA39

Primary completion for IVA trial (NCT05668741) in Cystic Fibrosis

Source
Phase 3

Suzetrigine Phase 3 Est. Readout

January 2027~Suzetrigine455

Primary completion for Suzetrigine trial (NCT06696443) in Diabetic Peripheral Neuropathic Pain

Source
Phase 2

VX-670 Phase 2 Est. Readout

February 2027~VX-67052

Primary completion for VX-670 trial (NCT06185764) in Myotonic Dystrophy Type 1 (DM1)

Source
Phase 2

VX-264 Phase 2 Est. Readout

March 2027~VX-2647

Estimated primary completion for VX-264 trial (NCT05791201) in Type 1 Diabetes. Topline data typically follows completion by weeks to months.

Source
Phase 2

VX-993 Phase 2 Est. Readout

March 2027~VX-993300

Estimated primary completion for VX-993 trial (NCT06619860) in Diabetic Peripheral Neuropathic Pain. Topline data typically follows completion by weeks to months.

Source

Upcoming FDA decisions

How VRTX's past catalysts played out

Phase 3 readoutMay 2026+8%

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaBOSTON6.1K employees
Website
Drug Pipeline

VX-017

Phase 3

Diabetes Mellitus, Type 1

Lumacaftor

Phase 3

Cystic Fibrosis

ELX/TEZ/IVA

Phase 3

Cystic Fibrosis

VX-661 plus ivacaftor combination

Phase 3

Cystic Fibrosis

IVA

Phase 3

Cystic Fibrosis

Tezacaftor/Ivacaftor

Phase 3

Cystic Fibrosis

LUM/IVA

Phase 3

Cystic Fibrosis

Ivacaftor

Phase 3

Cystic Fibrosis

Patent 2033

VX-445/TEZ/IVA

Phase 3

Cystic Fibrosis

VX-880

Phase 3

Type 1 Diabetes

OrphanFast TrackBreakthrough

TEZ

Phase 3

Cystic Fibrosis

TEZ/IVA

Phase 3

Cystic Fibrosis

Biological/Vaccine

Phase 3

Type 1 Diabetes

Casgevy

Exagamglogene Autotemcel

Phase 3

Sickle Cell Disease

OrphanFast TrackBreakthrough

VX-770

Phase 3

Cystic Fibrosis

Telaprevir

Phase 3

Hepatitis C

Patent 2028

VX-147

Phase 3

Proteinuric Kidney Disease

Lumacaftor Plus Ivacaftor Combination

Phase 3

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Suzetrigine

Phase 3

Pain

Patent 2040

VX-121/TEZ/D-IVA

Phase 3

Cystic Fibrosis

Povetacicept

Phase 3

Primary Membranous Nephropathy

CTX001

Phase 3

Beta-Thalassemia

VX-661/Ivacaftor

Phase 3

Cystic Fibrosis

Patent 2033

HB/APAP

Phase 3

Acute Pain

Pegylated Interferon Alfa 2a

Phase 3

Chronic Hepatitis C

Paltusotine

Phase 3

Acromegaly

Atumelnant

Phase 3

Congenital Adrenal Hyperplasia

SUZ

Phase 3

Acute Pain

VX-659/TEZ/IVA

Phase 3

Cystic Fibrosis

Suzetrigine (SUZ)

Phase 3

Acute Pain

LUM

Phase 3

Cystic Fibrosis

VX-509

Phase 3

Rheumatoid Arthritis

VX-809

Phase 3

Cystic Fibrosis

peginterferon alfa-2a

Phase 3

Hepatitis C

MP-424

Phase 3

Hepatitis C

Peginterferon Alfa-2b

Phase 3

Hepatitis C

pegylated interferon (Peg-IFN) alfa-2a

Phase 3

Hepatitis C, Chronic

VX-659

Phase 2

Cystic Fibrosis

VX-548

Phase 2

Acute Pain

Fast Track

VX-407

Phase 2

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

VX-661

Phase 2

Cystic Fibrosis

Cethrin

Phase 2

Spinal Cord Injury

ribavirin (fixed dose)

Phase 2

Hepatitis C

ribavirin (weight-based dose)

Phase 2

Hepatitis C

Tezacaftor/Ivacaftor + Ivacaftor

Phase 2

Cystic Fibrosis

VX-150

Phase 2

Osteoarthritis

VX-121 (Tablet)

Phase 2

Cystic Fibrosis

CRN09682

Phase 2

SST2-positive Neuroendocrine Neoplasms

atumelnant (CRN04894)

Phase 2

Congenital Adrenal Hyperplasia

VX-702

Phase 2

Rheumatoid Arthritis

P-1037

Phase 2

Cystic Fibrosis

Inaxaplin

Phase 2

Proteinuric Kidney Disease

Ribavirin (Copegus®)

Phase 2

Hepatitis C

VX-121

Phase 2

Cystic Fibrosis

VX-787

Phase 2

Influenza Virus

VX-222

Phase 2

Chronic Hepatitis C Virus

VX-993

Phase 2

Acute Pain

Telaprevir and Sofosbuvir

Phase 2

Hepatitis C, Chronic

PEG-Interferon-alpha 2a (Pegasys®)

Phase 2

Hepatitis C

VX-440

Phase 2

Cystic Fibrosis

VX-522 mRNA therapy

Phase 2

Cystic Fibrosis

VX-561

Phase 2

Cystic Fibrosis

VX-864

Phase 2

Alpha1-Antitrypsin Deficiency

VCH-759 (BCH-27759)

Phase 2

Hepatitis C, Chronic

VX-950

Phase 2

Hepatitis C

VX-135

Phase 2

Chronic Hepatitis C

VX-445

Phase 2

Cystic Fibrosis

Daclatasvir

Phase 2

Chronic Hepatitis C

VX-264

Phase 2

Type 1 Diabetes

VX-670

Phase 2

Myotonic Dystrophy Type 1 (DM1)

Merimepodib

Phase 2

Hepatitis C

VX-121 (Suspension)

Phase 2

Cystic Fibrosis

VX-152

Phase 2

Cystic Fibrosis

VX-765

Phase 2

Partial Epilepsy

Cystic Fibrosis

26 drugs in this indication

Acute Pain

5 drugs in this indication

Hepatitis C

3 drugs in this indication

Proteinuric Kidney Disease

2 drugs in this indication

Type 1 Diabetes

2 drugs in this indication

Rheumatoid Arthritis

2 drugs in this indication

Congenital Adrenal Hyperplasia

2 drugs in this indication

Beta-Thalassemia

1 drug in this indication

Spinal Cord Injury

1 drug in this indication

Pain

1 drug in this indication

Influenza Virus

1 drug in this indication

Primary Membranous Nephropathy

1 drug in this indication

Partial Epilepsy

1 drug in this indication

Osteoarthritis

1 drug in this indication

Chronic Hepatitis C Virus

1 drug in this indication

Myotonic Dystrophy Type 1 (DM1)

1 drug in this indication

Sickle Cell Disease

1 drug in this indication

Chronic Hepatitis C

1 drug in this indication

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

1 drug in this indication

Acromegaly

1 drug in this indication

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

1 drug in this indication

SST2-positive Neuroendocrine Neoplasms

1 drug in this indication

Diabetes Mellitus, Type 1

1 drug in this indication

Hepatitis C, Chronic

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

📑
Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
→

Frequently asked questions

What is in Vertex Pharmaceuticals Incorporated's drug pipeline?→

CatalystAlert tracks 74 drug candidates in Vertex Pharmaceuticals Incorporated's (VRTX) pipeline across Phase 3, Phase 2. Its lead program is Povetacicept (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Vertex Pharmaceuticals Incorporated's next FDA catalyst?→

Vertex Pharmaceuticals Incorporated's (VRTX) next tracked catalyst is a PDUFA date expected Nov 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track VRTX biotech catalysts?→

Add VRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vertex Pharmaceuticals Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply